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Prognostic Impact on Transplant Outcomes
after Allogeneic Peripheral Blood
Stem Cell Transplantation
Dong Hwan Kim,1,3 Gizelle Popradi,1 Wei Xu,2 Vikas Gupta,1 John Kuruvilla,1 Janice Wright,1
Hans A. Messner,1 Jeffrey H. Lipton1Peripheral eosinophilia after allogeneic stem cell transplant (ASCT) may reflect the activation of the Th2
cytokine pathway. A retrospective analysis was performed to evaluate the impact of early- (before day
100: EEo) or late-onset (beyond day 100: LEo) eosinophilia ($0.5 109/L in peripheral blood) on transplant
outcomes after peripheral blood SCT (PBSCT) in 237 patients. The incidence of EEo and LEo was 43% at day
100 and 62% at 2 years, respectively. Compared with patients without LEo, improved transplant outcomes
were observed in patients with LEo: better overall survival (OS; 86% versus 41%, P5 5 10211), lower non-
relapse mortality (NRM; 10% versus 37%, P5 3 1026), lower relapse incidence (11% versus 31%, P5 3
1025), and higher GVHD-specific survival (GSS; 90% versus 64%, P5 1 1026) were observed. In addition,
similar finding was observed when transplant outcomes were analyzed according to the occurrence of eo-
sinophilia at the onset of cGVHD. The multivariate analyses confirmed a favorable implication of LEo on OS,
NRM, and GSS. LEo was associated with: (1) less severe chronic GVHD (cGVHD), (2) higher prevalence of
autoantibodies, and (3) rapid lymphocyte count recovery after ASCT. In summary, the development of eo-
sinophila after allogeneic PBSCT seemed to be a prognostic marker for improving transplant outcome.
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6/j.bbmt.2009.01.003[1,2]. In the first report describing the disease entity of
cGVHD after allogeneic marrow transplant, elevated
eosinophil counts had been reported, especially in
patients with cGVHD [3]. Przepiorka et al. [4] also
observed eosinophilia in as many as 34% of patients
with cGVHD after allogeneic peripheral blood stem
cell transplantation (PBSCT), and noted that eosino-
philia occurred more frequently in patients with low-
risk cGVHD compared with those with high-risk
cGVHD (47% versus 12%, respectively). In addition,
Daneshpouy et al. [5] suggested the inflammation-
mediating role of eosinophils in the pathogenesis of
GVHD based on the findings that activated eosino-
phils were observed in gastrointestinal tract tissue of
patients with GVHD, and that eosinophil density cor-
related with GVHD severity.
Generally, peripheral blood eosinophilia has been
associated with underlying disease. Eosinophil efflux
from the bone marrow and in situ tissue accumulation
in response to local chemokine and cytokine release are
complex processes. In peripheral tissues such as lung,
skin, or gut, activated eosinophils may induce damage
through degranulation and release of stored471
472 Biol Blood Marrow Transplant 15:471-482, 2009D. H. Kim et al.inflammatory mediators including cytokines such as
interkeukin (IL)-3, IL-4, IL-5, IL-6, and granulocyte
macrophage-colony stimulating factor (GM-CSF).
The pathogenesis of cGVHD remains to be fully
understood. Different from aGVHD, which is medi-
ated by alloreactive cytotoxic T cell-lymphocyte acti-
vation and subsequent target organ inflammation
through the concerted actions of type 1 cytokines (ie,
tumor necrosis factor alpha [TNF-a] or interferon-g),
the pathogenesis of cGVHD is associated with
activation of Th2 cytokines such as IL-10, IL-4, IL-5,
or IL-6 [6,7], which are the eosinophilopoietic factors
[8,9]. Thus, eosinophilia after allogeneic stem cell
transplantation (ASCT) could be a surrogate marker
of activation of the Th2 pathway, which is located in
the center of the pathogenesis of cGVHD.
Previous investigations reported that the develop-
ment of peripheral blood eosinophilia within 100 days
(early-onset eosinophilia [EEo]) was a sign of favorable
transplant outcomes after (ASCT) [10,11]. However,
the occurrence of eosinophila is not limited to the first
100 days after PBSCT. It has also been observed beyond
day 100, and was potentially in association with active
cGVHD. Accordingly, the current study investigated
the clinical impact of either EEo (before day 100) or
late-onset (beyond day 100) eosinophilia (LEo) on
PBSCToutcomes in termsof overall survival (OS), non-
relapsemortality (NRM), recurrenceof primary disease,
and GVHD-specific survival (GSS) in 237 allogeneic
PBSCT recipients. Also, to evaluate the significance of
eosinophilia during the course of cGVHD, theprognos-
tic role of eosinophilia at the onset time of limited or ex-
tensive cGVHD has been also examined.METHODS AND MATERIALS
Transplant Procedures
A total of 237 consecutive patients who received
allogeneic PBSCTs from related donors between June
2001 and December 2006, at the Princess Margaret
Hospital, Toronto, Canada, were included in this retro-
spective study. Institutional research board review and
approval of the retrospective data collection and analysis
was obtained. Patient characteristics and transplant de-
tails are summarized in Table 1. All patients received
granulocyte-colony stimulating factor (G-CSF) mobi-
lized PBSC grafts collected as previously described
[12].The transplantationprocedures andposttransplan-
tation management adhered to previously described in-
stitutional policies [12-17]. Posttransplant G-CSF
support was not routinely administered.GVHD Prophylaxis and Treatment
The majority of GVHD prophylactic regimens in-
cluded cyclosporine (CsA; n 5 233). It was used eitheralone (n 5 6) or in combination with methotrexate
(MTX; n 5 152), mycophenolate mofetil (MMF;
n 5 71), or antithymocyte globulin (ATG; n 5 4).
Four patients received FK506 plus MTX. CsA taper
was initiated at 3months posttransplantation in patients
receiving from HLA-matched sibling or related donor,
and at 6months in recipients ofHLA-mismatched grafts
unless ongoing therapy ofGVHDnecessitated continu-
ation of systemic immunosuppressive treatment.
First-line treatment for aGVHD treatment was oral
prednisone, 1 mg/kg/day (n5 151) or i.v. methylpred-
nisolone, 2 mg/kg/day (n 5 15). Steroid refractory
aGVHD was defined by any of the following modified
criteria [18,19]: (1) progression of GVHD within 3
days of instituting treatment, (2) no change in GVHD
grade within 10 days, (3) incomplete resolution of
GVHD within 4 weeks, or (4) recurrence of GVHD
when the steroid dose reached\0.5 mg/kg/day. Steroid
refractory aGVHD was treated with second-line thera-
pies including high-dose i.v. methylprednisolone (2mg/
kg/day), a switch to FK506 from CsA, or institution of
ATG, pentostatin, rapamycin, and MMF according to
physician discretion.
Therapy of extensive cGVHD was decided after
considering an individual patient’s clinical status and
current immunosuppression. Steroid therapy was
used as the first-line regimen in patients not on immu-
nosuppression, whereas either steroids, CsA, or both
agents in combination were used in patients on immu-
nosuppression.When additional treatment was needed
to control cGVHD activity, a salvage regimen was in-
troduced according to each patient’s clinicalmanifesta-
tions or toxicity profiles. Salvage regimens included
azathioprine, hydrochloroquine, MMF, FK506, or
combination therapy.Definitions
The day of the stem cell infusion was defined as
day 0. Engraftment was defined as consecutive achieve-
ment of sustaining absolute neutrophil counts (ANC)
above 0.5  109/L for 2 days and peripheral platelet
counts exceeded 20  109/L for at least 3 consecutive
days without transfusion.
Eosinophilia was defined as an eosinophil count of
$0.5  109/L. EEo was defined as the peripheral
eosinophilia occurring before day 100 after PBSCT,
whereas late eosinophila (LEo) was defined as the
eosinophilia occurring beyond day 100 after PBSCT.
Disease risk was defined as described previously
[20]. aGVHD and cGVHD were diagnosed and
graded using established criteria [3,21]. The severity
of cGVHD was graded at the time of first manifesta-
tion of cGVHD using the Hopkins’ risk category
[22,23]. The Hopkins’ risk category consists of 3 risk
factors including progressive type onset, extensive
skin involvement (.50% of body surface area), and
Table 1. Properties of Patients and Transplant Procedures According to the Development of Late-Onset or Early-Onset Eosino-
philia after Allogeneic PBSCT
Overall Patients Early Eosinophilia No Early Eosinophilia Late eosinophilia No Late Eosinophilia
(n 5 237, 100%) (n 5 76, 32%) (n 5 161, 68%) P-Value (n 5 97, 50%) (n 5 98, 50%) P-Value
Recipients
Sex (F/M) 100/137 (42/58) 28/48 (37:63) 72/89 (45:55) NS 41/56 (42:58) 38/60 (39:61) NS
Age (years, median) 51.0 (18-71) 51.5 (18-69) 50.5 (18-71) NS 45.5 (18-71) 48.5 (19-67) NS
Diseases
AML/ALL 94/25 (40/10) 27/7 (36/9) 67/18 (42/11) NS 38/10 (39/10) 38/11 (39/11) NS
MDS/MF 18/12 (8/5) 10/1 (13/1) 8/11 (5/7) 8/3 (8/3) 9/6 (9/6)
CML/CLL 26/19 (11/8) 5/9 (7/12) 21/10 (13/6) 14/6 (14/6) 10/10 (10/10)
NHL/HD 37/3 (16/1) 13/3 (17/4) 24/0 (15/0) 15/2 (16/2) 12/1 (12/1)
MM/solid 1/2 (0/1) 0/1 (0/1) 1/1 (1/1) 1/0 (1/0) 0/1 (0/1)
Disease risk
Low/intermediate/high 23/191/23
(10/80/10)
6/63/7
(8/83/9)
17/128/16
(11/80/10)
NS 13/76/8
(13/78/8)
9/80/9
(9/82/9)
NS
Conditioning regimen
Myeloablative 162 (68) 43 (57) 119 (74) .002 71 (73) 68 (69) NS
TBI-/non-TBI based 120/42 (50/18) 26/17 (34/22) 94/25 (58/16) 56/15 (58/15) 49/19 (50/19)
Reduced intensity 75 (32) 33 (43) 42 (26) 26 (27) 30 (31)
GVHD prophylaxis
CsA + MTX/CsA + MMF 152/71 (64/30) 42/30 (55/40) 110/41 (68/26) NS 67/25 (69/26) 64/27 (65/28) NS
Others* 14 (6) 4 (5) 10 (6) 5 (5) 5 (5)
Cell dose
CD34+ cells (106/kg) 6.0 (2.2-18.7) 6.3 (2.7-16.6) 5.9 (2.2-18.7) NS 5.8 (2.3-18.7) 6.6 (2.3-16.9) NS
Donors
Sibling/family 224/13 (95/5) 72/4 (95/5) 152/9 (94/6) NS 89/8 (92/8) 95/3 (97/3) NS
HLA-disparity
Matched/1-Ag mm 214/23 (90)10 71/5 (93/7) 143/18 (89/11) NS 88/9 (92/8) 89/9 (91/9) NS
Engraftment
Neutrophil/platelet 232/228 (98/96) 76/76 (100/100) 156/152 (99/97) NS 97/97 (100/100) 98/94 (100/98) NS
Acute GVHD
Overall/Gr 2-4/Gr 3,4* 196/168/67
(83/71/28)
64/51/19
(84/67/25)
132/117/48
(84/75/31)
NS 87/73/20
(90/75/21)
80/74/35
(82/76/36)
NS
Steroid refractory 78/161 (48) 23/50 (46) 55/111 (50) NS 29 (42) 36 (51) NS
cGVHD
No/limited/extensive 31/29/145
(15/14/71)
6/11/90
(6/11/83)
25/18/55
(26/18/56)
<.001 10/11/52
(14/15/71)
34/20/88
(24/14/62)
NS
PBSCT indicates peripheral blood stem cell transplantation; F, female; M, male; S.E., standard error; AML, acute myelogenous leukemia; ALL, acute lym-
phoblastic leukemia; MDS, myelodysplastic syndrome; MF, myelofibrosis; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; NHL,
non-Hodgkin’ lymphoma; HD, Hodgkin’ disease; MM, multiple myeloma; CMV, cytomegalovirus; PBSC, peripheral blood stem cells; TBI, total body
irradiation; CsA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil; HLA, human leukocyte antigen; Ag, antigen; mm, mismatched.
*P 5 .02 between patients with and without late-onset eosinophilia.
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the patients into 3 risk groups according to their
survival.
The incidence of relapse was defined according to
the time from transplantation until disease progres-
sion. NRM was defined as death not related to disease
recurrence or progression. OS was defined as the time
from transplantation until death from any cause. GSS
was defined as the time from diagnosis of aGVHD or
cGVHD until death from GVHD-specific causes
including GVHD, infection associated with immuno-
suppressive treatment, or both.
Clinical Data
Clinical data was collected until the end of July
2007. Information about the following events was
recorded: peripheral cell engraftment (neutrophils,
platelets, lymphocytes, and eosinophils), aGVHD
and cGVHD, disease relapse, NRM, and deaths.Absolute eosinophil and lymphocyte counts were
recordedmonthly during the first 3months after trans-
plantation, then every 3 months until the end of year 1,
then every 6 months until year 3, and then at 3 years
after PBSCT.
Statistics
Patients’ characteristics, transplantation proce-
dures, and outcomes were compared according to the
development of EEo or LEo by chi-square, Fisher’s ex-
act, or Mann-Whitney’s U-tests. The cumulative inci-
dence of posttransplant eosinophilia was estimated
considering death as competing risk. The probabilities
of OS and GSS were estimated by Kaplan-Meier
methods, whereas the cumulative incidence of
GVHDwasestimatedconsideringdeathas acompeting
risk. The cumulative incidence of NRM was estimated
using relapse as a competing risk, and relapse incidence
using NRM as a competing risk. Transplantation
474 Biol Blood Marrow Transplant 15:471-482, 2009D. H. Kim et al.outcomes were compared by the log-rank test or Gray
test as appropriate.
The development of autoantibody and the severity
of cGVHD were compared using the chi-square test
according to the development of LEo. Serial changes
in absolute lymphocyte counts were compared using
the Student t-test.
The prognostic impact of clinical factors on OS,
NRM, relapse incidence, and GSS was examined by
uni- and multivariate analyses using the nontime-
dependent Cox proportional hazard model. Multivar-
iate survival analyses using the nontime-dependent
Cox proportional hazard model was performed with
forward conditional selection procedures. The univar-
iate analyses included the following variables: group-
ing by EEo (no EEo versus EEo), LEo (no LEo
versus LEo), conditioning regimen (myeloablative ver-
sus reduced intensity [RIC]), HLAmatching (matched
versusmismatched), donor type (sibling versus alterna-
tive), disease risk (low or intermediate versus high
risk), age of recipients (#50 years versus .50 years),
aGVHD (grade 0-ii versus grade iii-iv), steroid refrac-
tory aGVHD, cGVHD (absent versus present), and
extensive cGVHD (absent versus present).
To illustrate the effect of eosinophilia on survival,
‘‘semilandmark plots’’ were constructed for OS,
NRM, and relapse [24,25]. In patients who developed
peripheral blood eosinophilia, the posttransplant day
of development of eosinophilia was defined as the
landmark day; in patients who did not develop eosin-
ophilia, posttransplant day 196, which was the me-
dian day of onset of eosinophilia, was defined as the
landmark day. OS, NRM, and relapse was calculated
from the landmark day to the corresponding event or
date of last follow-up. In the same way, semilandmark
analysis also compared the GSS rates between the
cases with versus without eosinophila accounting
the onset day of overall or extensive cGVHD as land-
mark. In patients who did not develop eosinophilia,
posttransplant day 146 and day 271, which was the
respective median onset day of overall or extensive
cGVHD, was defined as the landmark day for
analysis.
To demonstrate a strong association between the
development of LEo and OS, we also performed
multivariate analyses using the time-dependent Cox
proportional hazard model. The occurrence of LEo,
the onset of any grade cGVHD, or the onset of exten-
sive cGVHD were treated as time-dependent covari-
ates in the model, whereas other prognostic factors
were treated as nontime categoric covariates. P\ .05
was considered significant. The hazard ratio (HR)
and 95% confidence interval (CI) were estimated
with a predetermined reference risk of 1.0. SPSS soft-
ware package (SPSS 13.0 Inc., Chicago, IL) and SAS
version 9.0 (SAS Institute, Cary, NC) were used for
the statistical analyses.RESULTS
The Serial Change of Peripheral Eosinophil
Counts after Allogeneic PBSCT
A biphasic pattern of eosinophilia was noted after
PBSCT. The first peak occurred prior to day 100
then the second one, beyond day 100. The incidence
of EEo at day 100 was 33.4% 6 3.1% (Figure 1A),
whereas that of LEo at 2 years after PBSCT was
61.7% 6 4.4% (Figure 1B). The median time for the
eosinophils counts over 0.5  109/L beyond day 100
after PBSCT was 196 days (95% CI, 277-453 days).
In most cases with LEo, a trend of rising eosinophil
counts were observed for 2 weeks to 4 months prior
to reach the level of 0.5  109/L of eosinophils.
GVHD after Allogeneic PBSCT
With a median follow-up duration of 31 months
among survivors (range: 2–71 months), the cumulative
incidence of aGVHD grades ii to iv and grades iii to iv
was 76.7% 6 3.0% and 47.6% 6 5.0%, respectively.
Of 166 patients who received steroid therapy for
grades ii to iv aGVHD, 161 patients were evaluated
for their responses. Good response to steroids was
noted in 83 patients (51.6%) and the remainders
(48.4%) were subsequently diagnosed with steroid
refractory GVHD.
The cumulative incidence of overall and extensive
cGVHD at 2 years was 91.6% 6 2.7% and 78.3% 6
3.4%, respectively. The median time to onset of over-
all and extensive cGVHD was 146 days (95% CI, 132-
160 days) and 271 days (95% CI, 223-319 days),
respectively. The development of limited cGVHD
was followed by the occurrence of LEowithin amedian
interval of 80 days, then by extensive cGVHD within
a median of 35 days following LEo occurrence. The
2-year GSS rate was estimated as 77.3% 6 3.1% after
the diagnosis of either aGVHD or cGVHD.
Early-Onset Eosinophilia and Its Contribution to
Transplantation Outcomes
The development of EEo was not associated with
the occurrence of grades iii-iv aGVHD (P 5 .1), but
there was a trend toward having more patients devel-
oping EEo in the group with grade ii-iv aGVHD com-
pared with those with grade 0 to i GVHD (P 5 .053).
When analyzed according to the organ-specific mani-
festations of aGVHD, EEo did not affect the develop-
ments of cutaneous (P 5 .07), gastrointestinal
(P5 .15), or hepatic GVHD (P5 .13). Steroid refrac-
tory aGVHDwas not associated with the development
of EEo (P 5 .7).
In univariate analyses, the group with EEo showed
a better OS (72.0% 6 5.9% versus 52.5 6 4.2% at 3
years, P 5 .002; Figure 2A), a lower NRM (20.8% 6
5.5% versus 32.0% 6 4.0% at 3 years, P 5 .05;
Figure 1. The probability of development of early-onset eosinophlia ($0.5  109/L) after allogeneic PBSC transplantation before day 100 (A) or the
probability of development of late-onset eosinophlia occuring beyond day 100 (B).
Biol Blood Marrow Transplant 15:471-482, 2009 475Eosinophilia after Allogeneic PBSCTFigure 2B), and a lower relapse (15.5% 6 4.7% versus
29.7% 6 4.4% at 3 years, P 5 .05; Figure 2C) com-
pared with the group without EEo, although no differ-
ence was observed in GSS (83.1% 6 4.7% versus
73.0% 6 4.1%, P 5 .2; Figure 2D).Late-Onset Eosinophilia Is Associated with
Improved Transplantation Outcomes after
Allogeneic PBSCT
Patients who had experienced previous episodes of
EEo showed a higher episode of LEo than those with-
out prior experience of EEo (73% versus 38%; P5 4
1026 by chi-square test, P 5 7  1025 by McNemar
test).Figure 2. The plots of the overall survival, nonrelapse mortality, relapse inci
velopment of early-onset eosinophilia before day 100 (A-D) and of late-onsetWith a median duration of follow-up of 773 days
and 679 days in the groups with and without LEo, sig-
nificant differences were observed between the 2
groups in terms of 3 year OS (86.3% 6 3.9% versus
46.2% 6 5.6%, P 5 5  10211; Figure 2E), NRM at
3 years (9.5% 6 3.3% versus 36.5% 6 5.6%, P5 3 
1026; Figure 2F), 3 years relapse incidence (10.8% 6
3.7% versus 30.5% 6 5.6%, P 5 3  1025;
Figure 2G) and 3 years GSS (90.4% 6 3.3% versus
64.5% 6 6.0%, P5 1  1025; Figure 2H).
With respect to cGVHD, no association of LEo
was observed with the occurrence of overall (P 5 .3)
or extensive cGVHD (P5 .5). When analyzed accord-
ing to the organ-specific manifestations of cGVHD,
LEo was significantly associated with more frequent
involvement of cutaneous (P 5 .001), oral (P 5 .04),dence, and GVHD-specific survival of patients with and without the de-
eosinophilia beyond day 100 (E-H).
476 Biol Blood Marrow Transplant 15:471-482, 2009D. H. Kim et al.ocular (P5 .02), and pulmonary GVHD (P5 .03), but
not of gastrointestinal (P 5 .2), hepatic (P 5 .7), or
musculoskeletal involvement (P 5 .6).Peripheral Blood Eosinophilia at the Time of
Onset of Overall or Extensive cGVHD after
Allogeneic PBSCT, and Its Prognostic Role
The peripheral blood eosinophilia at the onset of
first manifestation of cGVHD was documented in 47
of 171 patients having any grade of cGVHD (28%),
whereas it was noted in 66 of 137 patients having
extensive cGVHD (48%) at the onset time of extensive
cGVHD.
Significant differences of OS or NRM were
observed in favor of the patients presenting eosino-
philia when diagnosed initially with either any grade
of cGVHD (limited and extensive) or extensive
cGVHD. The group with eosinophilia at the onset
time of cGVHD showed a better OS (89.7% 6 5.0%
versus 66.6% 6 4.5% at 2 years, 5 .003; Figure 3A),
a lower NRM (6.8% 6 3.8% versus 24.5% 6 4.2%
at 2 years, P 5 .02; Figure 3B), but similar incidence
of relapse (9.2% 6 5.2% versus 11.4% 6 3.3% at 2
years, P 5 .4; Figure 3C) compared with the group
without eosinophilia.
These differences were more profound when ana-
lyzed according to the occurrence of eosinophilia at the
onset of extensive cGVHD. The group with eosinophiliaFigure 3. The plots of the overall survival, nonrelapse mortality, and relapse in
of onset of overall chronic GVHD (A-C) and of extensive chronic GVHD (D-at theonset timeof extensive cGVHDshowedabetterOS
(94.8%6 3.0% versus 49.7%6 6.5% at 2 years, P5 4
1028; Figure 3D), a lower NRM (3.3% 6 2.3% versus
41.5% 6 6.6% at 2 years, P 5 6  1027; Figure 3E),
but similar incidence of relapse (5.8% 6 5.2%
versus 12.2% 6 4.8% at 2 years, P 5 .2; Figure 3C)
compared with the group without eosinophilia.Late-Onset Eosinophilia Was Associated with
Less Severe Grade cGVHD at Diagnosis, Faster
Lymphocyte Count Recovery after
Transplantation, and the Development of
Autoantibodies during the Course of cGVHD
To explain why the patients developing late-onset
eosinophilia together with cGVHD, especially with
extensive cGVHD, had better transplant outcome
compared with those without eosinophilia, further
analyses were performed.
Forty-seven of 170 patients (28%) had eosinophilia
at the time of onset of cGVHD, whereas 66 of 137
(48%) had eosinophilia at the time of onset of extensive
cGVHD. The group developing LEo had less severe
cGVHD compared with those without LEo according
to the Hopkins’ grading system (P 5 .0004; Table 2).
In addition, when we compared the severity of
cGVHD according to the presence of eosinophilia,
especially at the time point of the onset of cGVHD,patients with versus without the development of eosinophilia at the time
F).
Biol Blood Marrow Transplant 15:471-482, 2009 477Eosinophilia after Allogeneic PBSCTthe patients both presenting eosinophilia and cGVHD
had milder degree of cGVHD compared with those
presenting cGVHD without evidence of eosinophilia
(P 5 .004; Table 3).
Lymphocyte reconstitution after PBSCT was
compared between the patients with and without,
LEo. As shown in Figure 4, the patients with LEo
showed a faster recovery of absolute lymphocyte
counts than those without LEo, which were signifi-
cantly different up to 9 months posttransplantation.
Thereafter, the lymphocyte counts became similar
between the 2 groups.
We collected data on the development of autoanti-
bodies during the course of cGVHD. Sixty-three pa-
tients were evaluated for the presence or titer of
antinuclear antibody (ANA) measured during the
course of cGVHD. A positive ANAwas noted in 38 pa-
tients (60%), and a titer of ANA over 1:160 was ob-
served in 21 patients (33%). Those who developed
a positive ANA had better OS and GSS compared
with those with a negative ANA (P 5 .009 for OS
and P5 .1 for GSS). Interestingly, a significant corre-
lation was noted between the development of LEo and
a positive ANA. A positive ANA was noted in 35 of 51
patients with LEo (69%), whereas it was only seen in 3
of 9 patients without LEo (33%, P 5 .04). Moreover,Table 2. The Association of the Late-Onset Eosinophilia with
the Severity of cGVHD and Organ Involvement
Late eosinophilia No late eosinophilia
(n 5 97, 50%) (n 5 98, 50%) P-Value
Seattle’s classification of cGVHD
No cGVHD 6 (6) 25 (26) <.001
Limited cGVHD 11 (11) 18 (18)
Extensive cGVHD 80 (83) 55 (56)
Hopkins’ risk category
Components of risk category
Progressive type onset 10/92 (11) 25/72 (35) .0002
Thrombocytopenia 18/92 (20) 32/73(44) .001
Extensive skin involvement 16/92 (17) 21/72 (29) .07
Severity of cGVHD by risk category
Mild grade 59/92 (64) 25/72 (35) .0004
Moderate grade 29/92 (32) 36/72 (50)
Severe grade 4/92 (4) 11/72 (15)
Organ involvements (n 5 91, 55%) (n 5 73, 44%)
Skin 73 (80) 40 (55) .0004
Oral 55 (60) 27 (37) .003
Ocular 26 (29) 6 (8) .001
Pulmonary 27 (30) 7 (10) .002
Gastrointestinal 31 (34) 34 (47) .1
Hepatic 71 (78) 54 (74) .5
Musculoskeletal 22 (24) 9 (12) .05
Deaths (n 5 97, 50%) (n 5 98, 50%)
Death 12 (12) 49 (50) <.001
Because of progression 4 (4) 20 (20) .6
Because of nonrelapse
mortality
8 (8) 29 (30)
GVHD 3 (3) 10 (10)
GVHD + infection 3 (3) 8 (8)
Infection 1 (1) 10 (10)
Others 1 (1) 1 (1)
GVHD indicates graft-versus-host disease; cGVHD, chronic GVHD.an ANA titer over 1:160 was observed in 21 of 51 pa-
tients with LEo (42%), but 0 of 9 patients without
LEo (0%, P 5 .02).
Multivariate Survival Analysis Using Nontime-
Dependent and Time-Dependent Cox’s
Proportional Hazard Model
A uni- and multivariate analysis using a Cox’s
proportional hazard model was performed to evaluate
the contribution of LEo to OS, NRM, relapse inci-
dence, and GSS in the context of other potentially
relevant clinical parameters (Table 4). The LEo,
rather than EEo, was identified as a significant favor-
able prognostic factor for OS (P 5 5  1026, HR
0.19, 95% CI [0.09-0.39]), NRM (P 5 .00005, HR
0.17 [0.07-0.41]), relapse incidence (P 5 .003, HR
0.21 [0.08-0.59]), and GSS (P 5 .00006, HR 0.17
[0.07-0.41]).
The beneficial effect of LEo on OS was proved
consistently (P 5 .0009, HR 0.32 [0.17-0.63]; Table
5) in the time-dependent Cox’s proportional hazard
model that was adopted to confirm the powerful inde-
pendent effect of LEo on transplant outcomes. Other
variables such as overall or extensive cGVHD, and
aGVHD grades iii to iv, were also identified as inde-
pendent prognostic factors for survival after PBSCT.
The Semilandmark Analysis for OS, NRM, and
Relapse
The group with eosinophilia showed a better OS
(86.7% 6 3.8% versus 61.4% 6 6.6% at 2 years, P 5
.00003; Figure 5A), a lower NRM (9.4%6 3.2% versus
24.3%6 5.8%at 2 years,P5 .02; Figure 5B), but similar
incidenceof relapse (8.7%6 3.2%versus 13.5%6 5.3%
at 2 years, P 5 .4; Figure 5C) compared with the
groupwithout eosinophilia in the semilandmark analysisTable 3. The Association of the Development of Peripheral
Blood Eosinophilia at the Time of First Manifestation of
chroinc GVHD with the Severity of cGVHD
At the Onset of Overall cGVHD
Eosinophilia No Eosinophilia
(n 5 47, 28%) (n 5 123, 72%) P-Value
Seattle’s classification of cGVHD
Limited cGVHD 12 (37) 20 (25) .2
Extensive cGVHD 35 (63) 103 (75)
Hopkins’ risk category
Components of risk category
Progressive type onset 3 (6) 33 (27) .004
Thrombocytopenia 6 (13) 44 (36) .004
Extensive skin involvement 7 (15) 32 (123) .1
Severity of cGVHD by risk category
Mild grade 34 (72) 54 (44) .004
Moderate grade 11 (23) 55 (45)
Severe grade 2 (4) 14 (11)
GVHD indicates graft-versus-host disease; cGVHD, chronic GVHD.
0 2 4 6 8 10 12 14 16 18 20 22 24
0.0
0.5
1.0
1.5
2.0
months after transplant
A
b
s
o
l
u
t
e
 
c
o
u
n
t
s
 
(
x
1
0
9
/
L
)
* *
No late eosinophilia
Late eosinophilia
*
* *
*
*
*
*
* p<0.05
** p<0.001
Figure 4. Serial change of absolute lymphocyte counts according to the
development of late eosinophila after allogeneic transplantation.
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to the corresponding events. Also, the group with
LEo showed better GSS rates compared with those
without LEo when semilandmark analyses were applied
accounting the onset day of overall (P 5 .00003;
Figure 5D) or extensive cGVHD as landmark
(P5 .0001; Figure 5E).DISCUSSION
The current study revealed the following findings:
(1) LEo after allogeneic PBSCT is a favorable prog-
nostic indicator for OS and GSS; (2) the occurrence
of eosinophilia together with cGVHD, especially
with extensive cGVHD, seemed to be a favorable
prognostic factor for OS and NRM; and (3) the favor-
able effect of LEo on transplant outcomes might be
from the association of LEo with a milder severity of
cGVHD, a higher precvelance of autoantibodies, and
faster lymphocyte count recovery after PBSCT.
Based on the finding that the development of
eosinophilia together with cGVHD, especially with
extensive cGVHD, can be a risk factor for OS and
NRM (Figures 3 and 5), it is possible to stratify the
patients with cGVHD into 2 subgroups having distinct
prognoses: cGVHD with eosinophilia and cGVHD
without eosinophilia. Herein, because eosinophilia
can be a simple marker of Th2 cytokine activation,
we propose that the biologic correlate of this stratifica-
tion is differences in levels of activation of the Th1 and
Th2 cytokine pathways: cGVHD with eosinophilia
may represent a predominance of Th2 activation com-
pared with Th1 activation, and the opposite may be
true when cGVHD is not associated with eosinophilia.
Further investigation is needed to validate the current
hypothesis to stratify the patients with cGVHD
according to the presence of eosinophila and to under-
stand their biologic basis at the level of cytokine or
gene expression profiles.
The beneficial effect of eosinophilia during the
course of cGVHD or in long-term outcomes ofPBSCT is supported by 3 key findings: (1) the group
that developed LEo presented with a milder severity
of cGVHD as scored by the Hopkins’ grading system.
When the severity of cGVHD was compared among
patients with and without LEo (Table 4), and accord-
ing to the presence of eosinophilia at the time that
cGVHD was diagnosed, we found that the group
with LEo presented with a milder grade of cGVHD.
We hypothesized that the group with the milder grade
of cGVHD at diagnosis in association with LEo had
a predominantly Th2 cytokine profile. (2) The group
with LEo demonstrated a higher prevalence of ANA
positivity compared with those without LEo. This
finding may reflect deregulated immunity or activity
of the humoral immune pathway. (3) Last, lymphocyte
count recovery was faster in the group with LEo com-
pared with those without LEo up to 9 to 12 months
after PBSCT (Figure 4). Alloreactive T cells stimu-
lated by the Th1 activation pathway attack the thymus
and delay the immune reconstitution of T cell-
lymphocytes [26,27]. Thus, lymphocyte recovery
could be expected to be faster in patients with LEo re-
flecting a state of lower Th1 cytokine activation. A cy-
tokine profile that is shifted from a Th1 to a Th2 state
may be associated with thymic sparing from damage
because of alloreactive T cells (Figure 6).
Several investigations have reported that autoanti-
body such as ANA or rheumatoid factor appear fre-
quently (20%-46%) after ASCT [28,29]. Patriarca
et al. [29] reported that the development of autoanti-
body after ASCT is related, not only to the
development of cGVHD, but also to faster B cell
immune recovery. These findings suggest a role for
humoral immunity in the pathogenesis of cGVHD
[30,31]. However, the prognostic significance of auto-
antibody on transplantation outcomes has yet to be
clarified.
Alloreactive donor T cells are believed to be key
mediators in the pathogenesis of GVHD. Th1 path-
way activation stimulates these lymphocytes, and plays
a central role in the deleterious effects of aGVHD in
humans. Conversely,Th2 pathway activation may
have a protective role against the effects of GVHD
[32-34]. There are evidences that activated tissue
eosinophils are linked to the pathogenesis of GVHD
[5,35]. The activation of eosinophils is mediated by
cytokines involved in the Th2 pathway including IL-
4, IL-5, and IL-6 [32-34]. A predominant Th2 periph-
eral blood cytokine profile may be associated with
a reciprocal decline in the activity of Th1 cytokines.
In addition, the B cell-mediated mechanism is also
involved in the pathogenesis of cGVHD given that
the rituximab is effective for the treatment of cGVHD
[36]. Furthermore, previous studies in a murine
GVHD model support the hypothesis that blockade
of the Th1 activation pathway during the course of
GVHD may result in the activation of the Th2
Table 4. Uni- andMultivariate Analyses to Evaluate theContribution of Late Eosinophilia in theContext of Clinical Risk Factors on
Overall Survival, Nonrelapse Mortality, Relapse Incidence, and GVHD-Specific Survival
Prognostic Factor
Univariate Multivariate
P-Value HR (95% CI) P-Value HR (95% CI))
Overall survival
Late eosinophilia .000000009 0.15 (0.08-0.29) 0.000005 0.19 (0.09-0.39)
Early eosinophilia .003 0.45 (0.27-0.76) NS —
RIC .08 1.46 (0.95-2.25) NS —
Mismatched transplant .4 1.28 (0.68-2.40) NS —
Sibling transplant .2 0.48 (0.15-1.51) NS —
High risk disease .008 2.17 (1.13-3.84) NS —
Old age (50 years or over) .004 1.87 (1.22-2.87) NS —
Steroid refractory aGVHD .002 2.16 (1.32-3.55) NS —
aGVHD, grade iii-iv .00005 2.40 (1.57-3.65) 0.01 2.05 (1.16-3.64)
Overall GVHD .000000000003 0.17 (0.10-0.27) 0.00003 0.23 (0.11-0.46)
Extensive GVHD .001 0.47 (0.29-0.75) NS —
Nonrelapse mortality
Late eosinophilia .00003 0.18 (0.08-0.40) 0.00005 0.17 (0.07-0.41)
Early eosinophilia .05 0.54 (0.29-1.00) NS —
RIC .9 0.96 (0.54-1.70) NS —
Mismatched transplant .1 1.76 (0.86-3.58) NS —
Sibling transplant .8 0.83 (0.26-2.65) NS —
High risk disease .002 2.78 (1.44-5.36) NS —
Old age (50 years or over) .008 2.10 (1.21-3.63) NS —
Steroid refractory aGVHD .00007 2.00 (0.00-7.82) 0.00006 3.87 (1.73-8.62)
Acute GVHD, grade 3-4 .00000003 4.73 (2.73-8.18) NS —
Overall GVHD .002 0.32 (0.16-0.66) NS —
Extensive GVHD .6 0.82 (0.42-1.59) NS —
Relapse incidence
Late eosinophilia .0001 0.21 (0.09-0.47) 0.003 0.21 (0.08-0.59)
Early eosinophilia .05 0.51 (0.25-1.00) NS —
RIC .0003 2.93 (1.64-5.24) NS —
Mismatched transplant .5 0.66 (0.20-2.12) NS —
Sibling transplant .3 0.31 (0.04-2.27) NS —
High risk disease .01 2.61 (1.22-5.61) NS —
Old age (50 years or over) .2 1.47 (0.82-2.65) NS —
Steroid refractory aGVHD .9 0.94 (0.46-1.95) NS —
Acute GVHD, grade 3-4 .3 0.68 (0.33-1.42) NS —
Overall GVHD .0000000000003 0.08 (0.04-0.16) 0.0000004 0.09 (0.04-0.23)
Extensive GVHD .0000004 0.19 (0.09-0.36) NS —
GVHD specific survival
Late eosinophilia .00007 0.20 (0.09-0.44) 0.00006 0.17 (0.07-0.41)
Early eosinophilia .2 0.66 (0.34-1.27) NS —
RIC .8 1.09 (0.57-2.12) NS —
Mismatched transplant .2 1.65 (0.74-3.71) NS —
Sibling transplant .6 0.65 (0.16-2.67) NS —
High risk disease .04 2.37 (1.06-5.32) NS —
Old age (50 years or over) .02 2.05 (1.11-3.77) NS —
Steroid refractory aGVHD .0001 3.87 (1.95-7.66) 0.0008 5.68 (2.43-13.25)
Acute GVHD, grade 3-4 .000000001 7.84 (4.04-15.21) NS —
Overall GVHD .08 0.44 (0.18-1.09) NS —
Extensive GVHD .7 1.17 (0.53-2.57) NS —
RIC, reduced-intensity conditioning; GVHD, graft-versus-host disease; HR, hazard ratio; 95% CI, 95% confidence interval; NS, not significant.
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tation of GVHD [37-39].
Because patients were ascertained and catego-
rized prior to establishment of the NIH consensus
criteria for diagnosis and stating of cGVHD in the
current study [40], our cohort may include some pa-
tients with late-onset aGVHD, a powerful adverse
prognostic factor for GSS [41,42]. Therefore, this
limitation needs to be addressed in future prospective
trials.
Previous studies have suggested that the develop-
ment of EEo might have a favorable implications ontransplantation outcomes [1,2]. However, based on
our findings, stronger association of LEo with trans-
plant outcomes was revealed in comparison with those
of EEo. The reason why significant association was
noted between EEo and transplant outcomes is from
strong correlation of the development of LEo with
prior episode of EEo.
The finding that LEo did not predict the risk of
cGVHD implies that the eosinophils-activating mech-
anism is not the only pathway to develop cGVHD.
The other pathway would include a Th1 activated, al-
loreactive cytotoxic T cell-mediated mechanism. The
Table 5. Multivariate Analysis for Overall Survival According to the Time-Dependent Cox’s Proportional Hazard Model
Prognostic Factor Parameter Estimate Chi-Square P-Value HR (95% CI)
Overall survival
Late eosinophilia 21.13414 11.0223 .0009 0.32 (0.17-0.63)
Overall GVHD 22.39024 18.9166 <.0001 0.09 (0.03-0.27)
Extensive GVHD 22.05429 14.9408 .0001 7.80 (2.75-22.11)
High risk disease 20.57434 2.7657 .1 1.78 (0.90-3.45)
Old age (50 years or over) 20.53244 4.7533 .03 1.69 (1.05-2.78)
Acute GVHD, grade 3-4 20.85984 11.6401 .0006 2.38 (1.45-3.85)
GVHD indicates graft-versus-host disease; HR, hazard ratio; 95% CI, 95% confidence interval.
480 Biol Blood Marrow Transplant 15:471-482, 2009D. H. Kim et al.better prognosis in the patients presenting eosino-
philia together with cGVHD suggest that GVHDpre-
dominantly induced by Th2 activation pathway, may
have a less severe course of cGVHD compared with
other subtype of Th1 predominating GVHD.
Herein, we suggest that (1) there seemed to be
a similarity between cGVHD associated with the
Th2 activation pathway and those associated with hu-
moral immunity, (2) the LEo could be a surrogate for
the cGVHD with the Th2 activation pathway, and (3)
the prognosis of cGVHD with the Th2 activation
pathway, presenting as eosinophilia, may be better
than those with cGVHD with predominantly a Th1
activation pathway.
In conclusion, peripheral blood eosinophilia (espe-
cially LEo) has favorable prognostic implications onFigure 5. Semilandmark analysis for the overall survival, nonrelapse mortality
development of eosinophilia (A-E).outcomes after allogeneic PBSCT. The benefits of
late-onset eosinophilia may be from a shift in the bal-
ance between the Th2 and Th1 cytokine activation
pathways during the course of cGVHD. Further stud-
ies are warranted to elucidate the causative mecha-
nism(s) behind the clinical benefits of LEo and to
validate its prognostic impact on ASCT outcomes.CONTRIBUTION OF THE AUTHORS
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